3 ms·
this is the conundrum the US Pharma is facing. GLP1 took NN 10+ years of investment to come up. Acquired podcast has a great story about them. The middleman is
by 8thcross 3y ago
this is the conundrum the US Pharma is facing. GLP1 took NN 10+ years of investment to come up. Acquired podcast has a great story about them. The middleman is what is different between the various country healthcare systems. USDOJ is trying/tried going after but one word - lobby. The regulation required is for consumer to directly buy from pharma skipping all middlemen. my 2cents.
- sudosysgen 3y agoNN didn't come up with GLP1. It's a natural peptide, and people have been taking it for a very long time. Nordisk did get it approved, yes, and that was costly, but let's not massively overstate the innovation. Semaglutide is not GLP1, it's a bit different. But it's not the first GLP1 analog. It's not even the first to be approved : AstraZeneca was the first to get a GLP1 agonist approved, in 2005. In fact, it even is used off label for obesity. Nordisk's big break was convincing the regulators to get it approved for obesity and not just type 2 diabetes.